Tymlos Shortage Update: What Patients Need to Know in 2026

If you've been struggling to fill your Tymlos (abaloparatide) prescription, you've probably wondered whether there's an official shortage. The answer is more nuanced than a simple yes or no — and understanding it can help you get your medication faster.

Is Tymlos on the FDA Shortage List in 2026?

No. As of 2026, Tymlos (abaloparatide) is not listed on the FDA drug shortage database or the ASHP (American Society of Health-System Pharmacists) shortage list. The manufacturer, Radius Health (now part of Ipsen), continues to produce and distribute abaloparatide.

However, this official status doesn't tell the full story. Many patients experience real difficulty accessing Tymlos — and those difficulties are driven by structural factors that have nothing to do with national supply levels.

Why Tymlos Feels Like It's in Shortage (Even Though It Isn't)

Tymlos is a specialty medication. It does not sit on shelves at standard retail pharmacies. It must be dispensed through specialty pharmacy networks, which handle medications requiring additional clinical support, cold-chain logistics, and insurance coordination. This creates a distribution bottleneck that affects the patient experience even when the drug itself is fully available nationally.

The key factors driving Tymlos access problems in 2026:

Specialty-only distribution: Tymlos is only dispensed through specialty pharmacies, not standard retail locations

Cold chain requirements: Requires refrigeration before first use, adding logistics complexity and shipping lead time

Mandatory prior authorization: Most insurance plans require PA before covering Tymlos, adding 3–10 days of processing time

Step therapy requirements: Many plans require patients to first try bisphosphonates before approving Tymlos

No generic available: Unlike teriparatide, abaloparatide has no generic version, keeping costs high and options narrow

A Brief History of Tymlos Availability

Tymlos was first approved by the FDA in April 2017 for postmenopausal women with osteoporosis at high risk of fracture. In January 2023, the FDA expanded the indication to include men with osteoporosis at high fracture risk, based on results from the Phase 3 ATOM trial. Since its launch, Tymlos has been produced without a major national supply disruption — but its specialty pharmacy distribution model has always created access friction.

Radius Health was acquired by Ipsen in 2022, bringing additional manufacturing and distribution resources to the Tymlos supply chain. As of 2026, the drug is considered commercially available through specialty pharmacy networks nationally.

What the Availability Data Tells Us

According to managed markets data (as cited by Radius Health through January 2026), approximately 88% of commercial insurance plans cover Tymlos. That's meaningful coverage — but each plan comes with its own prior authorization requirements, quantity limits, and formulary tier placement (Tymlos is typically Tier 5, the highest cost tier, on Medicare Part D plans).

The result is a medication that is technically available but practically hard to access — especially for patients who don't know to ask for help navigating the specialty pharmacy and insurance systems.

What Patients Can Do Right Now

If you're struggling to access Tymlos, here are the most effective steps you can take in 2026:

Use medfinder to find pharmacies with Tymlos in stock. medfinder calls pharmacies near you to find which ones can fill your prescription, saving you hours of calls.

Ask your doctor to start the PA process immediately. Don't wait until you're at the pharmacy. A proactive PA request from your doctor's office puts you days ahead.

Enroll in the Tymlos Savings Card. Commercially insured patients can pay as little as $0/month. Call 1-855-243-6222 or visit tymloshcp.com/access-and-savings.

If uninsured, apply for Radius Assist. Radius Health's patient assistance program may provide Tymlos at no cost to qualifying patients for up to 24 months.

Discuss alternatives with your doctor if needed. Teriparatide (with FDA-approved generics) or romosozumab may be more accessible depending on your insurance coverage.

Looking Ahead: Will Tymlos Get Easier to Access?

Several factors could improve Tymlos access in the coming years: continued formulary placement improvements, potential biosimilar or generic development as patents expire, and growing clinical recognition of abaloparatide's efficacy advantages over teriparatide. However, as of 2026, patients will still need to work through specialty pharmacy channels and insurance systems.

For a practical step-by-step approach to filling your prescription, see our guide to finding Tymlos in stock near you.